

Onxeo

R&D news

First significant milestone with AsiDNA achieved

Yesterday Onxeo announced its first preclinical proof-of-concept data with AsiDNA demonstrating the potential to be administrated intravenously. AsiDNA, a first-in-class DNA repair inhibitor, has already been tested in a Phase I trial with melanoma patients and showed promising results in terms of safety and initial signs of efficacy administered via local injection. After Onxeo acquired the drug in February 2016, the company repositioned the development and now seeking to establish a pre-clinical dossier to start human trials with intravenous injection, which would vastly increase the addressable indications. Yesterday's announcement was the first substantial step in this direction, as Onxeo showed that AsiDNA was effective alone or in combination with carboplatin in murine models of triple negative breast cancer (TNBC).

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/14	22.1	0.2	(0.05)	0.0	N/A	N/A
12/15	3.5	(20.0)	(0.44)	0.0	N/A	N/A
12/16	4.4	(20.4)	(0.48)	0.0	N/A	N/A
12/17e	7.8	(21.7)	(0.46)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, share-based payments

AsiDNA acts as a decoy that attracts DNA repair enzymes, leaving actual damaged DNA in cancerous cells (eg spontaneous or after treatment with chemotherapy) unrepaired, leading to cell death. Onxeo confirmed that this is achieved by hyper-activating two key DNA repair proteins, DNA-PK and PARP, which are then 'distracted' from repairing the actual DNA damage. From the data released so far, AsiDNA standalone significantly decreased tumour growth in the TNBC model and improved survival. Onxeo also tested the drug in combination with the classic neoadjuvant (ie given before surgery) chemotherapy, carboplatin. Despite AsiDNA being administered in lower doses than in the standalone trial, the combination with carboplatin outperformed other arms (untreated, low dose AsiDNA alone or carboplatin alone).

Next, Onxeo will also study AsiDNA administered together with PARP inhibitors, which target more downstream single-strand break repair pathways, and therefore the combination with AsiDNA could have interesting synergies. PARP inhibitors piqued the market's interest after the first drug Lynparza (olaparib, AstraZeneca) was launched in late 2014 and brought \$218m in sales in 2016. EvaluatePharma estimates sales of all PARP inhibitors will total to \$4.6bn by 2022.

Onxeo indicated that it aims to file the investigational new drug application by end-2017, which will likely allow initiation of Phase I in H118, in our view. The Phase I trial will be in a variety of tumours, which will allow selecting the best indication to progress forward. Onxeo is also working on a potential biomarker, so called micronuclei, to stratify the patient population according to the likelihood of response to treatment. If successful, this would be a particularly attractive pathway for standalone treatment with AsiDNA.

Pharma & biotech

6 July 2017

Price €4.14

Market cap €209m

Net cash (€m) at end-Q117 22

Shares in issue 50.6m

Free float 85%

Code ONXEO

Primary exchange Euronext Paris

Secondary exchange OMX Copenhagen

Share price performance



Business description

Onxeo is focused on orphan cancer and has three orphan oncology assets in various stages of development (Livatag, belinostat and AsiDNA). Royalty-earning Beleodaq (belinostat) is launched in the US, along with two non-core, partnered, specialty products.

Analyst

Jonas Peciulis +44 (0)20 3077 5728

healthcare@edisongroup.com
[Edison profile page](#)

**Onxeo is a research client of
Edison Investment Research
Limited**

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Onxeo and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.